Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China.
10.1007/s11684-023-1043-5
- Author:
Dong WEI
1
;
Yusang XIE
2
;
Xuefei LIU
2
;
Rong CHEN
2
;
Min ZHOU
2
;
Xinxin ZHANG
1
;
Jieming QU
3
Author Information
1. Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
3. Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jmqu0906@163.com.
- Publication Type:Review
- Keywords:
SARS-CoV-2;
clinical features;
coronavirus disease 2019;
epidemiology
- MeSH:
Humans;
COVID-19;
SARS-CoV-2;
Pneumonia, Viral/prevention & control*;
Global Health;
China/epidemiology*
- From:
Frontiers of Medicine
2023;17(6):1030-1046
- CountryChina
- Language:English
-
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported at the end of 2019 as a worldwide health concern causing a pandemic of unusual viral pneumonia and many other organ damages, which was defined by the World Health Organization as coronavirus disease 2019 (COVID-19). The pandemic is considered a significant threat to global public health till now. In this review, we have summarized the lessons learnt during the emergence and spread of SARS-CoV-2, including its prototype and variants. The overall clinical features of variants of concern (VOC), heterogeneity in the clinical manifestations, radiology and pathology of COVID-19 patients are also discussed, along with advances in therapeutic agents.
